{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:17Z","timestamp":1792782857971,"version":"4.5.0"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH, NEW DELHI, INDIA","award":["02\/(0107)\/12\/EMR-II"],"award-info":[{"award-number":["02\/(0107)\/12\/EMR-II"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s10072-016-2625-7","type":"journal-article","created":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T05:52:49Z","timestamp":1464760369000},"page":"1403-1435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Current pharmacotherapy and putative disease-modifying therapy for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"37","author":[{"given":"Akanksha","family":"Kulshreshtha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Piplani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"2625_CR1","unstructured":"National Institute of Health. MedlinePlus: Alzheimer\u2019s disease. http:\/\/www.nlm.nih.gov\/medlineplus\/alzheimersdisease.html . Accessed 10 Nov 2015"},{"key":"2625_CR2","unstructured":"National Institute on Aging. Alzheimer\u2019s Disease Education and Referral Center. Alzheimer\u2019s Disease Fact Sheet. http:\/\/www.nia.nih.gov\/alzheimers\/publication\/alzheimers-disease-fact-sheet . Accessed 10 Nov 2015"},{"key":"2625_CR3","unstructured":"Alzheimer\u2019s Disease Education and Referral Center. About Alzheimer\u2019s disease: Alzheimer\u2019s basics. https:\/\/www.nia.nih.gov\/alzheimers\/topics\/alzheimers-basics . Accessed 10 Nov 2015"},{"key":"2625_CR4","unstructured":"NIH Senior Health. Alzheimer\u2019s disease. http:\/\/nihseniorhealth.gov\/alzheimersdisease\/whatisalzheimersdisease\/01.html . Accessed 14 Nov 2015"},{"key":"2625_CR5","unstructured":"2015 Alzheimer\u2019s disease facts and figures. http:\/\/www.alz.org\/facts\/ . Accessed 14 Nov 2015"},{"key":"2625_CR6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","volume":"52","author":"A Delacourte","year":"1999","unstructured":"Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P et al (1999) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer\u2019s disease. Neurology 52:1158\u20131165","journal-title":"Neurology"},{"key":"2625_CR7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.disamonth.2010.06.001","volume":"56","author":"RJ Castellani","year":"2010","unstructured":"Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer disease. Dis Mon 56:484\u2013546","journal-title":"Dis Mon"},{"key":"2625_CR8","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2165\/11595870-000000000-00000","volume":"71","author":"N Herrmann","year":"2011","unstructured":"Herrmann N, Chau SA, Kircanski I, Lanctot KL (2011) Current and emerging drug treatment options for Alzheimer\u2019s disease: a systematic review. Drugs 71:2031\u20132065","journal-title":"Drugs"},{"key":"2625_CR9","first-page":"1","volume":"1019","author":"HG Lee","year":"2014","unstructured":"Lee HG, Casadesus G, Zhu X, Takeda A, Perry G, Smith MA (2014) Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann N Y Acad Sci 1019:1\u20134","journal-title":"Ann N Y Acad Sci"},{"key":"2625_CR10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0022-510X(77)90073-9","volume":"34","author":"EK Perry","year":"1977","unstructured":"Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34:247\u2013265","journal-title":"J Neurol Sci"},{"key":"2625_CR11","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1212\/WNL.27.8.783","volume":"27","author":"D Drachman","year":"1977","unstructured":"Drachman D (1977) Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27:783\u2013790","journal-title":"Neurology"},{"key":"2625_CR12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/archneur.1974.00490320001001","volume":"30","author":"D Drachman","year":"1974","unstructured":"Drachman D, Leavitt J (1974) Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30:113\u2013121","journal-title":"Arch Neurol"},{"key":"2625_CR13","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1126\/science.7058341","volume":"215","author":"PJ Whitehouse","year":"1982","unstructured":"Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer\u2019s disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237\u20131239","journal-title":"Science"},{"key":"2625_CR14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/archpsyc.1988.01800340028004","volume":"45","author":"PA Newhouse","year":"1988","unstructured":"Newhouse PA, Sunderland T, Tariot PN, Weingartner H, Thomason K, Mellow AM et al (1988) The effects of acute scopolamine in geriatric depression. Arch Gen Psychiatry 45:906\u2013912","journal-title":"Arch Gen Psychiatry"},{"key":"2625_CR15","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199210293271801","volume":"327","author":"KL Davis","year":"1992","unstructured":"Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI et al (1992) A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer\u2019s disease. N Engl J Med 327:1253\u20131259","journal-title":"N Engl J Med"},{"key":"2625_CR16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"PT Francis","year":"1999","unstructured":"Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137\u2013147","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2625_CR17","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.281.15.1401","volume":"281","author":"KL Davis","year":"1999","unstructured":"Davis KL, Mohs RC, Marin D (1999) Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 281:1401\u20131406","journal-title":"JAMA"},{"key":"2625_CR18","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.281.15.1433","volume":"281","author":"P Davies","year":"1999","unstructured":"Davies P (1999) Challenging the cholinergic hypothesis in Alzheimer disease. JAMA 281:1433\u20131434","journal-title":"JAMA"},{"key":"2625_CR19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s004019900178","volume":"100","author":"I Sassin","year":"2000","unstructured":"Sassin I, Schultz C, Thal DR, Rub U, Arai K, Braak E et al (2000) Evolution of Alzheimer\u2019s disease-related cytoskeletal changes in the basal nucleus of meynert. Acta Neuropathol 100:259\u2013269","journal-title":"Acta Neuropathol"},{"key":"2625_CR20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2174\/156720507781788855","volume":"4","author":"EJ Mufson","year":"2007","unstructured":"Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD (2007) Cholinotrophicmolecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 4:340\u2013350","journal-title":"Curr Alzheimer Res"},{"key":"2625_CR21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0197-4580(92)90113-C","volume":"13","author":"EK Perry","year":"1992","unstructured":"Perry EK, Johnson M, Kerwin JM, Piggott MA, Court JA, Shaw PJ et al (1992) Convergent cholinergic activities in aging and Alzheimer\u2019s disease. Neurobiol Aging 13:393\u2013400","journal-title":"Neurobiol Aging"},{"key":"2625_CR22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bbr.2009.12.044","volume":"221","author":"A Contestabile","year":"2011","unstructured":"Contestabile A (2011) The history of the cholinergic hypothesis. Behav Brain Res 221:334\u2013340","journal-title":"Behav Brain Res"},{"key":"2625_CR23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00697388","volume":"61","author":"T Arendt","year":"1983","unstructured":"Arendt T, Bigl V, Arendt A, Tennstedt A (1983) Loss of neurons in the nucleus basalis of meynert in Alzheimer\u2019s disease, paralysis agitans and Korsakoff\u2019s disease. Acta Neuropathol 61:101\u2013108","journal-title":"Acta Neuropathol"},{"key":"2625_CR24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0959-4388(95)80022-0","volume":"5","author":"M Gallagher","year":"1995","unstructured":"Gallagher M, Colombo PJ (1995) Ageing: the cholinergic hypothesis of cognitive decline. Curr Opin Neurobiol 5:161\u2013168","journal-title":"Curr Opin Neurobiol"},{"key":"2625_CR25","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1038\/399a023","volume":"399","author":"DJ Selkoe","year":"1999","unstructured":"Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer\u2019s disease. Nature 399:A23\u2013A31","journal-title":"Nature"},{"key":"2625_CR26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/354432a0","volume":"354","author":"DJ Selkoe","year":"1991","unstructured":"Selkoe DJ (1991) Alzheimer\u2019s disease in the beginning. Nature 354:432\u2013433","journal-title":"Nature"},{"key":"2625_CR27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","volume":"325","author":"J Kang","year":"1987","unstructured":"Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH et al (1987) The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733\u2013736","journal-title":"Nature"},{"key":"2625_CR28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev.cb.10.110194.002105","volume":"10","author":"DJ Selkoe","year":"1994","unstructured":"Selkoe DJ (1994) Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer\u2019s disease. Annu Rev Cell Biol 10:373\u2013403","journal-title":"Annu Rev Cell Biol"},{"key":"2625_CR29","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","volume":"283","author":"J Naslund","year":"2000","unstructured":"Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P et al (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571\u20131577","journal-title":"JAMA"},{"key":"2625_CR30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2006.12.008","volume":"26","author":"M Ohno","year":"2007","unstructured":"Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R et al (2007) BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP\/PS1 transgenic mice. Neurobiol Dis 26:134\u2013145","journal-title":"Neurobiol Dis"},{"key":"2625_CR31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe DJ (2001) Alzheimer\u2019s disease: genes, proteins and therapy. Physiol Rev 81:741\u2013766","journal-title":"Physiol Rev"},{"key":"2625_CR32","doi-asserted-by":"crossref","first-page":"11049","DOI":"10.1073\/pnas.96.20.11049","volume":"96","author":"S Sinha","year":"1999","unstructured":"Sinha S, Lieberburg I (1999) Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 96:11049\u201311053","journal-title":"Proc Natl Acad Sci USA"},{"key":"2625_CR33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/361260a0","volume":"361","author":"P Seubert","year":"1993","unstructured":"Seubert P, Oltersdorf T, Lee MG, Barbour R, Blomquist C, Davis DL (1993) Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature 361:260\u2013263","journal-title":"Nature"},{"key":"2625_CR34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev.pharmtox.43.100901.140248","volume":"43","author":"DJ Selkoe","year":"2003","unstructured":"Selkoe DJ, Schenk D (2003) Alzheimer\u2019s disease: molecular understanding predicts amyloid-based therapeutics. Ann Rev Pharmacol Toxicol 43:545\u2013584","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"2625_CR35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng0892-345","volume":"1","author":"M Mullan","year":"1992","unstructured":"Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B et al (1992) A pathogenic mutation for probable Alzheimer\u2019s disease in the APP Gene at the N-terminus of beta-amyloid. Nat Genet 1:345\u2013347","journal-title":"Nat Genet"},{"key":"2625_CR36","doi-asserted-by":"crossref","first-page":"11993","DOI":"10.1073\/pnas.91.25.11993","volume":"91","author":"M Citron","year":"1994","unstructured":"Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J et al (1994) Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 91:11993\u201311997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2625_CR37","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/nbdi.1996.0003","volume":"3","author":"CA Lemere","year":"1996","unstructured":"Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3:16\u201332","journal-title":"Neurobiol Dis"},{"key":"2625_CR38","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.410430316","volume":"43","author":"VP Prasher","year":"1998","unstructured":"Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC et al (1998) Molecular mapping of Alzheimer-type dementia in Down\u2019s syndrome. Ann Neurol 43:380\u2013383","journal-title":"Ann Neurol"},{"key":"2625_CR39","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0006-291X(84)91209-9","volume":"122","author":"GG Glenner","year":"1984","unstructured":"Glenner GG, Wong CW (1984) Alzheimer\u2019s disease and Down\u2019s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122:1131\u20131135","journal-title":"Biochem Biophys Res Commun"},{"key":"2625_CR40","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245\u20134249","journal-title":"Proc Natl Acad Sci USA"},{"key":"2625_CR41","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ (2002) Alzheimer\u2019s disease is a synaptic failure. Science 298:789\u2013791","journal-title":"Science"},{"key":"2625_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1461145705005833","volume":"9","author":"RM Lane","year":"2006","unstructured":"Lane RM, Potkin SG, Enz A (2006) Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9:101\u2013124","journal-title":"Int J Neuropsychopharmacol"},{"key":"2625_CR43","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0896-6273(00)80108-7","volume":"16","author":"NC Inestrosa","year":"1996","unstructured":"Inestrosa NC, Alvarez A, P\u00e9rez CA, Moreno RD, Vicente M, Linker C et al (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer\u2019s fibrils: possible role of the peripheral site of the enzyme. Neuron 16:881\u2013891","journal-title":"Neuron"},{"key":"2625_CR44","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/bi9813577","volume":"38","author":"T Szegletes","year":"1999","unstructured":"Szegletes T, Mallender WD, Thomas PJ, Rosenberry TL (1999) Substrate binding to the peripheral site of acetylcholinesterase initiates enzymatic catalysis. Substrate inhibition arises as a secondary effect. Biochemistry 38:122\u2013133","journal-title":"Biochemistry"},{"key":"2625_CR45","doi-asserted-by":"crossref","first-page":"6296","DOI":"10.1016\/S0021-9258(17)37371-4","volume":"269","author":"D Barak","year":"1994","unstructured":"Barak D, Kronman C, Ordentlich A, Ariel N, Bromberg A, Marcus D et al (1994) Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem 269:6296\u20136305","journal-title":"J Biol Chem"},{"key":"2625_CR46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/14756360701421294","volume":"22","author":"J Wiesner","year":"2007","unstructured":"Wiesner J, Kriz Z, Kuca K, Jun D, Koca J (2007) Acetylcholinesterases-the structural similarities and differences. J Enzyme Inhib Med Chem 22:417\u2013424","journal-title":"J Enzyme Inhib Med Chem"},{"key":"2625_CR47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","volume":"11","author":"MB Colovic","year":"2013","unstructured":"Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM (2013) Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol 11:315\u2013335","journal-title":"Curr Neuropharmacol"},{"key":"2625_CR48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1749-6632.1996.tb34451.x","volume":"777","author":"E Giacobini","year":"1996","unstructured":"Giacobini E, Mori F, Lai CC (1996) The effect of cholinesterase inhibitors on the secretion of apps from rat brain cortex. Ann N Y Acad Sci 777:393\u2013398","journal-title":"Ann N Y Acad Sci"},{"key":"2625_CR49","unstructured":"Alzheimer\u2019s Association. FDA approved treatments for Alzheimer\u2019s disease. http:\/\/www.alz.org\/dementia\/downloads\/topicsheet_treatments.pdf . Accessed 15 Dec 2015"},{"key":"2625_CR50","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jama.1994.03510370037029","volume":"271","author":"MJ Knapp","year":"1994","unstructured":"Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI (1994) A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer\u2019s disease. The tacrine study group. JAMA 271:985\u2013991","journal-title":"JAMA"},{"key":"2625_CR51","first-page":"211","volume":"3","author":"RA Hansen","year":"2008","unstructured":"Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE (2008) Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis. Clin Interv Aging 3:211\u2013225","journal-title":"Clin Interv Aging"},{"key":"2625_CR52","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejmech.2013.09.050","volume":"70","author":"M Singh","year":"2013","unstructured":"Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D (2013) Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur J Med Chem 70:165\u2013188","journal-title":"Eur J Med Chem"},{"key":"2625_CR53","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.phymed.2007.02.002","volume":"14","author":"PK Mukherjee","year":"2007","unstructured":"Mukherjee PK, Kumar V, Mal M, Houghton PJ (2007) Acetylcholinesterase inhibitors from plants. Phytomedicine 14:289\u2013300","journal-title":"Phytomedicine"},{"key":"2625_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(95)00682-6","volume":"296","author":"M Misztal","year":"1996","unstructured":"Misztal M, Frankiewicz T, Parsons CG, Danysz W (1996) Learning deficits induced by chronic intraventricular infusion of quinolinic acid-protection by MK-801 and memantine. Eur J Pharmacol 296:1\u20138","journal-title":"Eur J Pharmacol"},{"key":"2625_CR55","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1602\/neurorx.1.1.101","volume":"1","author":"SA Lipton","year":"2004","unstructured":"Lipton SA (2004) Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1:101\u2013110","journal-title":"NeuroRx"},{"key":"2625_CR56","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0028-3908(99)00060-X","volume":"38","author":"T Frankiewicz","year":"1999","unstructured":"Frankiewicz T, Parsons CG (1999) Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology 38:1253\u20131259","journal-title":"Neuropharmacology"},{"key":"2625_CR57","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1476-5381.1996.tb15245.x","volume":"117","author":"T Frankiewicz","year":"1996","unstructured":"Frankiewicz T, Potier B, Bashir ZI, Collingridge GL, Parsons CG (1996) Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol 117:689\u2013697","journal-title":"Br J Pharmacol"},{"key":"2625_CR58","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1111\/j.1460-9568.2008.06498.x","volume":"28","author":"MS Song","year":"2008","unstructured":"Song MS, Rauw G, Baker GB, Kar S (2008) Memantine protects rat cortical cultured neurons against \u03b2-amyloid-induced toxicity by attenuating tau phosphorylation. Eur J Neurosci 28:1989\u20132002","journal-title":"Eur J Neurosci"},{"key":"2625_CR59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine study group (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317\u2013324","journal-title":"JAMA"},{"key":"2625_CR60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/WAD.0b013e31816653bc","volume":"22","author":"A Atri","year":"2008","unstructured":"Atri A, Shaughnessy LW, Locascio JJ, Growdon JH (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 22:209\u2013221","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2625_CR61","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1747-0285.2012.01317.x","volume":"79","author":"M Espinoza-Moraga","year":"2012","unstructured":"Espinoza-Moraga M, Caballero J, Gaube F, Winckler T, Santos LS (2012) 1-Benzyl-1,2,3,4-tetrahydro-carboline as channel blocker of N-methyl-d-aspartate receptors. Chem Biol Drug Des 79:594\u2013599","journal-title":"Chem Biol Drug Des"},{"key":"2625_CR62","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.bmc.2013.12.040","volume":"22","author":"R Gitto","year":"2014","unstructured":"Gitto R, De Luca L, Ferro S, Ruso E, Sarro GD, Chisari M et al (2014) Synthesis, modeling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors. Bioorg Med Chem 22:1040\u20131048","journal-title":"Bioorg Med Chem"},{"key":"2625_CR63","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1523\/JNEUROSCI.3657-09.2009","volume":"29","author":"R Vassar","year":"2009","unstructured":"Vassar R, Kovacs DM, Yan R, Wong PC (2009) The beta-secretase enzyme BACE in health and Alzheimer\u2019s disease: regulation, cell biology, function, and therapeutic potential. J Neurosci 29:12787\u201312794","journal-title":"J Neurosci"},{"key":"2625_CR64","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/hmg\/10.12.1317","volume":"10","author":"SL Roberds","year":"2001","unstructured":"Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS et al (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer\u2019s disease therapeutics. Hum Mol Genet 10:1317\u20131324","journal-title":"Hum Mol Genet"},{"key":"2625_CR65","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","volume":"4","author":"Y Luo","year":"2001","unstructured":"Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P et al (2001) Mice deficient in BACE1, the Alzheimer\u2019s beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4:231\u2013232","journal-title":"Nat Neurosci"},{"key":"2625_CR66","doi-asserted-by":"crossref","first-page":"9712","DOI":"10.1073\/pnas.160115697","volume":"97","author":"M Farzan","year":"2000","unstructured":"Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H (2000) BACE2, a beta- secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci USA 97:9712\u20139717","journal-title":"Proc Natl Acad Sci USA"},{"key":"2625_CR67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.02.008","volume":"68","author":"P Benes","year":"2008","unstructured":"Benes P, Vetvicka V, Fusek M (2008) Cathepsin D\u2014many functions of one aspartic protease. Crit Rev Oncol Hematol 68:12\u201328","journal-title":"Crit Rev Oncol Hematol"},{"key":"2625_CR68","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1074\/jbc.M109266200","volume":"277","author":"F Gruninger-Leitch","year":"2002","unstructured":"Gruninger-Leitch F, Schlatter D, K\u00fcng E, Nelb\u00f6ck P, Dobeli H (2002) Substrate and inhibitor profile of BACE (beta-secretase) and comparison with other mammalian aspartic proteases. J Biol Chem 277:4687\u20134693","journal-title":"J Biol Chem"},{"key":"2625_CR69","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1021\/bi0498252","volume":"43","author":"L Hong","year":"2004","unstructured":"Hong L, Tang J (2004) Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis. Biochemistry 43:4689\u20134695","journal-title":"Biochemistry"},{"key":"2625_CR70","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrn2168","volume":"8","author":"FM LaFerla","year":"2007","unstructured":"LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer\u2019s disease. Nat Rev Neurosci 8:499\u2013509","journal-title":"Nat Rev Neurosci"},{"key":"2625_CR71","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nurt.2008.05.007","volume":"5","author":"AK Ghosh","year":"2008","unstructured":"Ghosh AK, Gemma S, Tang J (2008) Beta-secretase as a therapeutic target for Alzheimer\u2019s disease. Neurotherapeutics 5:399\u2013408","journal-title":"Neurotherapeutics"},{"key":"2625_CR72","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1021\/jm0101803","volume":"44","author":"AK Ghosh","year":"2001","unstructured":"Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA et al (2001) Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 44:2865\u20132868","journal-title":"J Med Chem"},{"key":"2625_CR73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/156720508783954730","volume":"5","author":"AK Ghosh","year":"2008","unstructured":"Ghosh AK, Kumaragurubaran N, Hong L, Koelsh G, Tang J (2008) Memapsin 2 (beta-secretase) inhibitors: drug development. Curr Alzheimer Res 5:121\u2013131","journal-title":"Curr Alzheimer Res"},{"key":"2625_CR74","unstructured":"John V, Tung J, Fang L, Mamo SS (2000) Statine-derived tetrapeptide inhibitors of beta-secretase. Int. Patent WO2000077030, 2000"},{"key":"2625_CR75","unstructured":"Peters S, Fuchs K, Eickmeier C, Stransky W, Dorner-Ciossek C, Handschuh S, Nar H, Klinder K, Kostka M (2007) Statine derivatives for the treatment of Alzheimer\u2019s Disease III. US Patent US7238774, 2007"},{"key":"2625_CR76","unstructured":"Peters S, Fuchs K, Eickmeier C, Stransky W, Dorner-Ciossek C, Handschuh S, Nar H, Klinder K, Kostka M (2006) Statine derivatives for the treatment of Alzheimer\u2019s Disease III. US Patent US20060100158, 2006"},{"key":"2625_CR77","unstructured":"Peters S, Fuchs K, Eickmeier C, Stransky W, Dorner-Ciossek C, Handschuh S, Nar H, Klinder K, Kostka M (2006) Statine derivatives for the treatment of Alzheimer\u2019s Disease. Int. Patent WO2006050861, 2006"},{"key":"2625_CR78","unstructured":"Kiso Y (2007) Peptide derivatives having \u03b2-secretase inhibitory activity. US Patent US7312188, 2007"},{"key":"2625_CR79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bmcl.2004.09.090","volume":"15","author":"T Kimura","year":"2005","unstructured":"Kimura T, Shuto D, Hamada Y, Igawa N, Kasai S, Liu P et al (2005) Design and synthesis of highly active Alzheimer\u2019s beta-secretase (BACE1) inhibitors, KMI-420 And KMI-429, with enhanced chemical stability. Bioorg Med Chem Lett 15:211\u2013215","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR80","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bmc.2010.11.042","volume":"19","author":"F Wangsell","year":"2011","unstructured":"Wangsell F, Nordeman P, S\u00e4vmarker J, Emanuelsson R, Jansson K, Lindberg J et al (2011) Investigation of \u03b1-phenylnorstatine and \u03b1-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 inhibitors. Bioorg Med Chem 19:145\u2013155","journal-title":"Bioorg Med Chem"},{"key":"2625_CR81","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1021\/jm0607451","volume":"49","author":"DC Cole","year":"2006","unstructured":"Cole DC, Manas ES, Stock JR, Condon JS, Jennings LD, Aulabaugh A et al (2006) Acylguanidines as small-molecule beta-secretase inhibitors. J Med Chem 49:6158\u20136159","journal-title":"J Med Chem"},{"key":"2625_CR82","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bmcl.2007.11.043","volume":"18","author":"LD Jennings","year":"2008","unstructured":"Jennings LD, Cole DC, Stock JR, Sukhdeo MN, Ellingboe JW, Cowling R et al (2008) Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1\u2032 substrate binding pocket. Bioorg Med Chem Lett 18:767\u2013771","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR83","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bmcl.2007.12.010","volume":"18","author":"DC Cole","year":"2008","unstructured":"Cole DC, Stock JR, Chopra R, Cowling R, Ellingboe JW, Fan KY et al (2008) Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. Bioorg Med Chem Lett 18:1063\u20131066","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR84","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/jm061197u","volume":"50","author":"M Congreve","year":"2007","unstructured":"Congreve M, Aharony D, Albert J, Callaghan O, Campbell J, Carr RA et al (2007) Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. J Med Chem 50:1124\u20131132","journal-title":"J Med Chem"},{"key":"2625_CR85","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.bmcl.2010.02.075","volume":"20","author":"MS Malamas","year":"2010","unstructured":"Malamas MS, Barnes K, Hui Y, Johnson M, Lovering F, Condon J et al (2010) Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors. Bioorg Med Chem Lett 20:2068\u20132073","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR86","unstructured":"Malamas MS, Fobare WF, Solvibile Jr WR, Lovering FE, Condon JS, Robichaud AJ (2006) Amino-pyridines as inhibitors of beta-secretase. US Patent US20060173049, 2006"},{"key":"2625_CR87","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejmech.2011.12.016","volume":"48","author":"G Chiriano","year":"2012","unstructured":"Chiriano G, De Simone A, Mancini F, Perez DI, Cavalli A, Bolognesi ML et al (2012) A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: structure-based design, synthesis, and biological evaluation. Eur J Med Chem 48:206\u2013213","journal-title":"Eur J Med Chem"},{"key":"2625_CR88","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.1021\/jm9006752","volume":"52","author":"MS Malamas","year":"2009","unstructured":"Malamas MS, Erdei J, Gunawan I, Barnes K, Johnson M, Hui Y et al (2009) Aminoimidazoles as potent and selective human beta-secretase (BACE1) inhibitors. J Med Chem 52:6314\u20136323","journal-title":"J Med Chem"},{"key":"2625_CR89","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bmcl.2011.11.024","volume":"22","author":"SJ Stachel","year":"2012","unstructured":"Stachel SJ, Steele TG, Petrocchi A, Haugabook SJ, McGaughey G, Katharine Holloway M et al (2012) Discovery of pyrrolidine-based \u03b2-secretase inhibitors: lead advancement through conformational design for maintenance of ligand binding efficiency. Bioorg Med Chem Lett 22:240\u2013244","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR90","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.bmcl.2009.04.033","volume":"19","author":"SJ Stachel","year":"2009","unstructured":"Stachel SJ, Coburn CA, Rush D, Jones KL, Zhu H, Rajapakse H et al (2009) Discovery of aminoheterocycles as a novel beta-secretase inhibitor class: pH dependence on binding activity part 1. Bioorg Med Chem Lett 19:2977\u20132980","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR91","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1021\/jm400225m","volume":"56","author":"H Hilpert","year":"2013","unstructured":"Hilpert H, Guba W, Woltering TJ, Wostl W, Pinard E, Mauser H et al (2013) \u03b2-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer\u2019s disease. J Med Chem 56:3980\u20133995","journal-title":"J Med Chem"},{"key":"2625_CR92","doi-asserted-by":"crossref","first-page":"6203","DOI":"10.1016\/j.bmcl.2010.08.111","volume":"20","author":"W Xu","year":"2010","unstructured":"Xu W, Chen G, Zhu W, Zuo Z (2010) Molecular docking and structure-activity relationship studies on benzothiazole based non-peptidic BACE-1 inhibitors. Bioorg Med Chem Lett 20:6203\u20136207","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR93","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1016\/j.bmcl.2003.09.018","volume":"13","author":"SY Jeon","year":"2003","unstructured":"Jeon SY, Bae K, Seong YH, Song KS (2003) Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett 13:3905\u20133908","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR94","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.phymed.2006.09.003","volume":"14","author":"SY Jeon","year":"2007","unstructured":"Jeon SY, Kwon SH, Seong YH, Bae K, Hur JM, Lee YY et al (2007) Beta-secretase (BACE1)-inhibiting stilbenoids from Smilax rhizoma. Phytomedicine 14:403\u2013408","journal-title":"Phytomedicine"},{"key":"2625_CR95","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ptr.2967","volume":"24","author":"S Marumoto","year":"2010","unstructured":"Marumoto S, Miyazawa M (2010) \u03b2-secretase inhibitory effects of furanocoumarins from the root of Angelica dahurica. Phytother Res 24:510\u2013513","journal-title":"Phytother Res"},{"key":"2625_CR96","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.bmc.2011.12.002","volume":"20","author":"S Marumoto","year":"2012","unstructured":"Marumoto S, Miyazawa M (2012) Structure-activity relationships for naturally occurring coumarins as \u03b2-secretase inhibitor. Bioorg Med Chem 20:784\u2013788","journal-title":"Bioorg Med Chem"},{"key":"2625_CR97","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.bbagen.2008.01.017","volume":"1780","author":"Y Shimmyo","year":"2008","unstructured":"Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H (2008) Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta 1780:819\u2013825","journal-title":"Biochim Biophys Acta"},{"key":"2625_CR98","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1016\/j.bmcl.2011.03.060","volume":"21","author":"JK Cho","year":"2011","unstructured":"Cho JK, Ryu YB, Curtis-Long MJ, Kim JY, Kim D, Lee S et al (2011) Inhibition and structural reliability of prenylated flavones from the stem bark of Morus ihou on \u03b2-secretase (BACE-1). Bioorg Med Chem Lett 21:2945\u20132948","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR99","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.fitote.2012.08.002","volume":"83","author":"J Tao","year":"2012","unstructured":"Tao J, Zhao J, Zhao Y, Cui Y, Fang W (2012) BACE inhibitory flavanones from Balanophora involucrata Hook. f. Fitoterapia 83:1386\u20131390","journal-title":"Fitoterapia"},{"key":"2625_CR100","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1016\/j.bmcl.2010.04.093","volume":"20","author":"HA Jung","year":"2010","unstructured":"Jung HA, Oh SH, Choi JS (2010) Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett 20:3211\u20133215","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR101","unstructured":"Alzforum. Therapeutics LY2886721. http:\/\/www.alzforum.org\/therapeutics\/ly2886721 . Accessed 11 Jan 2016"},{"key":"2625_CR102","unstructured":"Alzforum. Therapeutics Verubecestat. http:\/\/www.alzforum.org\/therapeutics\/verubecestat . Accessed 11 Jan 2016"},{"key":"2625_CR103","unstructured":"Merck Clinical Trials. An efficacy and safety trial of the investigational drug MK-8931 in mild to moderate Alzheimer\u2019s disease (MK-8931 017). http:\/\/www.merck.com\/clinical-trials\/infographics\/P07738 . Accessed 11 Jan 2016"},{"key":"2625_CR104","unstructured":"Astra Zeneca. AstraZeneca and Lilly announce alliance to develop and commercialise BACE inhibitor AZD3293 for Alzheimer\u2019s disease. https:\/\/www.astrazeneca.com\/our-company\/media-centre\/pressreleases\/2014\/astrazeneca-lilly-bace-inhibitor-azd3293-alzheimers-disease-16092014 . Accessed 11 Jan 2016"},{"key":"2625_CR105","unstructured":"National Institute of Aging. Alzheimer\u2019s Disease Education and Referral Centre. AZD3293 in early Alzheimer\u2019s disease (AMARANTH). https:\/\/www.nia.nih.gov\/alzheimers\/clinical-trials\/azd3293-early-alzheimers-disease-amaranth . Accessed 11 Jan 2016"},{"key":"2625_CR106","unstructured":"ClinicalTrials.gov. A drug-drug interaction study of AZD3293 (LY3314814) in healthy participants. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02406261 . Accessed 11 Jan 2016"},{"key":"2625_CR107","unstructured":"Alzforum. Therapeutics E2609. http:\/\/www.alzforum.org\/therapeutics\/E2609 . Accessed 11 Jan 2016"},{"key":"2625_CR108","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 369:341\u2013350","journal-title":"N Engl J Med"},{"key":"2625_CR109","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.1021\/bi301137h","volume":"51","author":"CJ Crump","year":"2012","unstructured":"Crump CJ, Castro SV, Wang F, Pozdnyakov N, Ballard TE, Sisodia SS et al (2012) BMS-708,163 targets presenilin and lacks notch-sparing activity. Biochemistry 51:7209\u20137211","journal-title":"Biochemistry"},{"key":"2625_CR110","unstructured":"EU Clinical Trials Register. Clinical trials for BMS-708163. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=BMS-708163 . Accessed 28 Jan 2016"},{"key":"2625_CR111","unstructured":"Bristol Meyer Squibb. Pipeline Asset Update for BMS-708163 (gamma secretase inhibitor). http:\/\/www.bms.com\/research\/investigational\/alzheimers\/Pages\/BMS708163.aspx . Accessed 28 Jan 2016"},{"key":"2625_CR112","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","volume":"69","author":"V Coric","year":"2012","unstructured":"Coric V, Van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW et al (2012) Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69:1430\u20131440","journal-title":"Arch Neurol"},{"key":"2625_CR113","first-page":"1","volume":"28","author":"V Coric","year":"2015","unstructured":"Coric V, Salloway S, Van Dyck CH, Dubois B, Andreasen N, Brody M et al (2015) Targeting prodromal Alzheimer\u2019s disease with avagacestat: a randomized clinical trial. JAMA Neurol 28:1\u201310","journal-title":"JAMA Neurol"},{"key":"2625_CR114","unstructured":"Alzforum. More Evidence that \u03b3-Secretase Modulators Spare Essential Substrates. http:\/\/www.alzforum.org\/news\/research-news\/more-evidence-g-secretase-modulators-spare-essential-substrates . Accessed 29 Jan 2016"},{"key":"2625_CR115","doi-asserted-by":"crossref","first-page":"18664","DOI":"10.1074\/jbc.M301619200","volume":"278","author":"Y Takahashi","year":"2003","unstructured":"Takahashi Y, Hayashi I, Tominari Y, Rikimaru K, Morohashi Y, Kan T et al (2003) Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces abeta 42 generation. J Biol Chem 278:18664\u201318670","journal-title":"J Biol Chem"},{"key":"2625_CR116","doi-asserted-by":"crossref","first-page":"30748","DOI":"10.1074\/jbc.M304824200","volume":"278","author":"S Weggen","year":"2003","unstructured":"Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH (2003) Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) And ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 278:30748\u201330754","journal-title":"J Biol Chem"},{"key":"2625_CR117","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/156802608783334097","volume":"8","author":"I Peretto","year":"2008","unstructured":"Peretto I, La Porta E (2008) Gamma-secretase modulation and its promise for Alzheimer\u2019s disease: a medicinal chemistry perspective. Curr Top Med Chem 8:38\u201346","journal-title":"Curr Top Med Chem"},{"key":"2625_CR118","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/WAD.0b013e31815d1048","volume":"21","author":"D Galasko","year":"2007","unstructured":"Galasko D, Graff-Radford N, May S, Hendrix S, Cottrell B, Sagi S et al (2007) Safety, tolerability, pharmacokinetics, and A\u03b2 levels after short-term administration of R-flurbiprofen in healthy elderly individuals. Alzheimer Dis Assoc Disord 21:292\u2013299","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2625_CR119","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1021\/jm0610200","volume":"49","author":"R Narlawar","year":"2006","unstructured":"Narlawar R, P\u00e9rez Revuelta BI, Haass C, Steiner H, Schmidt B, Baumann K (2006) Scaffold of the cyclooxygenase-2 (cox-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem 49:7588\u20137591","journal-title":"J Med Chem"},{"key":"2625_CR120","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.bmcl.2009.08.072","volume":"20","author":"A Hall","year":"2010","unstructured":"Hall A, Elliott RL, Giblin GM, Hussain I, Musgrave J, Naylor A et al (2010) Piperidine-derived gamma-secretase modulators. Bioorg Med Chem Lett 20:1306\u20131311","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR121","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bmcl.2009.11.101","volume":"20","author":"A Rivkin","year":"2010","unstructured":"Rivkin A, Ahearn SP, Chichetti SM, Kim YR, Li C, Rosenau A et al (2010) Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 20:1269\u20131271","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR122","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.bmcl.2010.02.008","volume":"20","author":"A Rivkin","year":"2010","unstructured":"Rivkin A, Ahearn SP, Chichetti SM, Hamblett CL, Garcia Y, Martinez M et al (2010) Purine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 20:2279\u20132282","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR123","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/cn3000857","volume":"3","author":"MA Findeis","year":"2012","unstructured":"Findeis MA, Schroeder F, McKee TD, Yager D, Fraering PC, Creaser SP et al (2012) Discovery of a novel pharmacological and structural class of gamma secretase modulators derived from the extract of Actaea Racemosa. ACS Chem Neurosci 3:941\u2013951","journal-title":"ACS Chem Neurosci"},{"key":"2625_CR124","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1046\/j.1471-4159.1996.67051882.x","volume":"67","author":"K Furukawa","year":"1996","unstructured":"Furukawa K, Sopher B, Rydel R, Begley J, Pham D, Martin G et al (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase derived secreted amyloid precursor protein conferred by a C-terminal heparin binding domain. J Neurochem 67:1882\u20131896","journal-title":"J Neurochem"},{"key":"2625_CR125","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1523\/JNEUROSCI.14-04-02117.1994","volume":"14","author":"D Small","year":"1994","unstructured":"Small D, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K et al (1994) A heparin-binding domain in the amyloid protein precursor of Alzheimer\u2019s disease is involved in the regulation of neurite outgrowth. J Neurosci 14:2117\u20132127","journal-title":"J Neurosci"},{"key":"2625_CR126","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1073\/pnas.96.7.3922","volume":"96","author":"S Lammich","year":"1999","unstructured":"Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M et al (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 96:3922\u20133927","journal-title":"Proc Natl Acad Sci USA"},{"key":"2625_CR127","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbr.2006.08.030","volume":"175","author":"U Schmitt","year":"2006","unstructured":"Schmitt U, Hiemke C, Fahrenholz F, Schroeder A (2006) Overexpression of two different forms of the alpha-secretase ADAM10 affects learning and memory in mice. Behav Brain Res 175:278\u2013284","journal-title":"Behav Brain Res"},{"key":"2625_CR128","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.neurobiolaging.2006.11.004","volume":"29","author":"KFS Bell","year":"2008","unstructured":"Bell KFS, Zheng L, Fahrenholz F, Cuello AC (2008) ADAM-10 over-expression increases cortical synaptogenesis. Neurobiol Aging 29:554\u2013565","journal-title":"Neurobiol Aging"},{"key":"2625_CR129","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/science.1411529","volume":"258","author":"RM Nitsch","year":"1992","unstructured":"Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304\u2013307","journal-title":"Science"},{"key":"2625_CR130","doi-asserted-by":"crossref","first-page":"44881","DOI":"10.1074\/jbc.M109008200","volume":"276","author":"S Robert","year":"2001","unstructured":"Robert S, Zugaza J, Fischmeister R, Gardier A, Lezoualc\u2019h F (2001) The human serotonin 5-HT4 receptor regulates secretion of nonamyloidogenic precursor protein. J Biol Chem 276:44881\u201344888","journal-title":"J Biol Chem"},{"key":"2625_CR131","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuropharm.2012.11.009","volume":"67","author":"E Siopi","year":"2013","unstructured":"Siopi E, Llufriu-Daben G, Cho AH, Vidal-Lletjos S, Plotkine M, Marchand-Leroux C et al (2013) Etazolate, an \u03b1-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice. Neuropharmacology 67:183\u2013192","journal-title":"Neuropharmacology"},{"key":"2625_CR132","first-page":"28","volume":"8","author":"F Gervais","year":"2001","unstructured":"Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, Mclaughlin R et al (2001) Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 8:28\u201335","journal-title":"Amyloid"},{"key":"2625_CR133","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","volume":"28","author":"F Gervais","year":"2007","unstructured":"Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M et al (2007) Targeting soluble A\u03b2 peptide with tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 28:537\u2013547","journal-title":"Neurobiol Aging"},{"key":"2625_CR134","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2004","unstructured":"Citron M (2004) Alzheimer\u2019s disease: strategies for disease modification. Nat Rev Drug Discov 9:387\u2013398","journal-title":"Nat Rev Drug Discov"},{"key":"2625_CR135","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","volume":"67","author":"P Aisen","year":"2006","unstructured":"Aisen P, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P et al (2006) A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 67:1757\u20131763","journal-title":"Neurology"},{"key":"2625_CR136","unstructured":"Transition Therapeutics Announces Results of Data Analysis from ELND005 Phase 2\/3 Clinical Study in Agitation and Aggression in Alzheimer\u2019s Disease Patients. http:\/\/www.prnewswire.com\/news-releases\/transition-therapeutics-announces-results-of-data-analysis-from-elnd005-phase-23-clinical-study-in-agitation-and-aggression-in-alzheimers-disease-patients-533007951.html . Accessed 9 Feb 2016"},{"key":"2625_CR137","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/jnc.12454","volume":"128","author":"A Hoshino","year":"2014","unstructured":"Hoshino A, Helwig M, Rezaei S, Berridge C, Eriksen JL, Lindberg I (2014) A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer\u2019s disease. J Neurochem 128:419\u2013430","journal-title":"J Neurochem"},{"key":"2625_CR138","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C et al (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer\u2019s disease model. Nat Neurosci 5:452\u2013457","journal-title":"Nat Neurosci"},{"key":"2625_CR139","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553\u20131562","journal-title":"Neurology"},{"key":"2625_CR140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev.neuro.31.060407.125529","volume":"31","author":"D Brody","year":"2008","unstructured":"Brody D, Holtzman D (2008) Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 31:175\u2013193","journal-title":"Annu Rev Neurosci"},{"key":"2625_CR141","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC et al (2003) Sub acute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61:46\u201354","journal-title":"Neurology"},{"key":"2625_CR142","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","volume":"24","author":"RS Black","year":"2010","unstructured":"Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A et al (2010) A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 24:198\u2013203","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2625_CR143","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"S Salloway","year":"2009","unstructured":"Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M et al (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061\u20132070","journal-title":"Neurology"},{"key":"2625_CR144","unstructured":"Alzforum. Therapeutics Rember TM. http:\/\/www.alzforum.org\/therapeutics\/rember-tm . Accessed 12 Feb 2016"},{"key":"2625_CR145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4161\/auto.19048","volume":"8","author":"EE Congdon","year":"2012","unstructured":"Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS et al (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8:609\u2013622","journal-title":"Autophagy"},{"key":"2625_CR146","doi-asserted-by":"crossref","first-page":"11024","DOI":"10.1074\/jbc.M112.436006","volume":"288","author":"A Crowe","year":"2013","unstructured":"Crowe A, James MJ, Lee VM, Smith AB 3rd, Trojanowski JQ, Ballatore C et al (2013) Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation. J Biol Chem 288:11024\u201311037","journal-title":"J Biol Chem"},{"key":"2625_CR147","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-142874","volume":"44","author":"CM Wischik","year":"2015","unstructured":"Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM et al (2015) Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease. J Alzheimers Dis 44:705\u2013720","journal-title":"J Alzheimers Dis"},{"key":"2625_CR148","unstructured":"Adis Insight. Drug Profile TRx 0237. http:\/\/adisinsight.springer.com\/drugs\/800034429 . Accessed 16 Feb 2016"},{"key":"2625_CR149","unstructured":"TauRx Therapeutics. http:\/\/taurx.com\/taurx-005-enrolment.html . Accessed 16 Feb 2016"},{"key":"2625_CR150","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s00018-007-7221-9","volume":"64","author":"K Iqbal","year":"2007","unstructured":"Iqbal K, Grundke-Iqbal I (2007) Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci 64:2234\u20132244","journal-title":"Cell Mol Life Sci"},{"key":"2625_CR151","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1471-4159.2006.04139.x","volume":"99","author":"T Engel","year":"2006","unstructured":"Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F (2006) Chronic lithium administration to FTDP-17 tau and GSK-3\u03b2 overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99:1445\u20131455","journal-title":"J Neurochem"},{"key":"2625_CR152","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1523\/JNEUROSCI.0604-06.2006","volume":"26","author":"T Engel","year":"2006","unstructured":"Engel T, Hernandez F, Avila J, Lucas JJ (2006) Full reversal of Alzheimer\u2019s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26:5083\u20135090","journal-title":"J Neurosci"},{"key":"2625_CR153","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/JAD-2003-5405","volume":"5","author":"M Perez","year":"2003","unstructured":"Perez M, Hernandez F, Lim F, D\u00edaz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5:301\u2013308","journal-title":"J Alzheimers Dis"},{"key":"2625_CR154","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1074-5521(00)00063-6","volume":"7","author":"L Meijer","year":"2000","unstructured":"Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH et al (2000) Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 7:51\u201363","journal-title":"Chem Biol"},{"key":"2625_CR155","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1046\/j.1432-1327.2000.01673.x","volume":"267","author":"M Leost","year":"2000","unstructured":"Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM et al (2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5\/P25. Eur J Biochem 267:5983\u20135994","journal-title":"Eur J Biochem"},{"key":"2625_CR156","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1074\/jbc.M002466200","volume":"276","author":"S Leclerc","year":"2001","unstructured":"Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL et al (2001) Indirubins inhibit glycogen synthase kinase-3 beta and CDK5\/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer\u2019s disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 276:251\u2013260","journal-title":"J Biol Chem"},{"key":"2625_CR157","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.febslet.2004.04.047","volume":"566","author":"L Li","year":"2004","unstructured":"Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K (2004) Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett 566:261\u2013269","journal-title":"FEBS Lett"},{"key":"2625_CR158","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1016\/j.febslet.2006.06.021","volume":"580","author":"MO Chohan","year":"2006","unstructured":"Chohan MO, Khatoon S, Iqbal IG, Iqbal K (2006) Involvement of I 2 PP2A in the abnormal hyperphosphorylation of tau and its reversal by memantine. FEBS Lett 580:3973\u20133979","journal-title":"FEBS Lett"},{"key":"2625_CR159","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","volume":"107","author":"E Kickstein","year":"2010","unstructured":"Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J et al (2010) Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA 107:21830\u201321835","journal-title":"Proc Natl Acad Sci USA"},{"key":"2625_CR160","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neuropharm.2010.01.016","volume":"59","author":"B Bulic","year":"2010","unstructured":"Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E (2010) Tau protein and tau aggregation inhibitors. Neuropharmacology 59:276\u2013289","journal-title":"Neuropharmacology"},{"key":"2625_CR161","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.celrep.2013.03.027","volume":"3","author":"M Varjosalo","year":"2013","unstructured":"Varjosalo M, Keskitalo S, Van Drogen A, Nurkkala H, Vichalkovski A, Aebersold R et al (2013) The protein interaction landscape of the human CMGC kinase group. Cell Rep 3:1306\u20131320","journal-title":"Cell Rep"},{"key":"2625_CR162","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/hmg\/5.9.1305","volume":"5","author":"J Guimer\u00e1","year":"1996","unstructured":"Guimer\u00e1 J, Casas C, Pucharcos C, Solans A, Dom\u00e8nech A, Planas AM et al (1996) A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. Hum Mol Genet 5:1305\u20131310","journal-title":"Hum Mol Genet"},{"key":"2625_CR163","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1007\/s00018-009-0123-2","volume":"66","author":"J Park","year":"2009","unstructured":"Park J, Song WJ, Chung KC (2009) Function and regulation of DYRK1A: towards understanding Down syndrome. Cell Mol Life Sci 66:3235\u20133240","journal-title":"Cell Mol Life Sci"},{"key":"2625_CR164","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","volume":"278","author":"J Wegiel","year":"2011","unstructured":"Wegiel J, Gong CX, Hwang YW (2011) The role of DYRK1A in neurodegenerative diseases. FEBS J 278:236\u2013245","journal-title":"FEBS J"},{"key":"2625_CR165","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1471-4159.2007.05075.x","volume":"104","author":"SR Ryoo","year":"2008","unstructured":"Ryoo SR, Cho HJ, Lee HW, Jeong HK, Radnaabazar C, Kim YS et al (2008) Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer\u2019s disease. J Neurochem 104:1333\u20131344","journal-title":"J Neurochem"},{"key":"2625_CR166","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1471-4159.2010.06769.x","volume":"115","author":"YS Ryu","year":"2010","unstructured":"Ryu YS, Park SY, Jung MS, Yoon SH, Kwen MY, Lee SY et al (2010) DYRK1A mediated phosphorylation of presenilin-1: a functional link between down syndrome and Alzheimer\u2019s disease. J Neurochem 115:574\u2013584","journal-title":"J Neurochem"},{"key":"2625_CR167","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/hmg\/ddl437","volume":"16","author":"R Kimura","year":"2007","unstructured":"Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H et al (2007) The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 16:15\u201323","journal-title":"Hum Mol Genet"},{"key":"2625_CR168","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nbd.2005.03.020","volume":"20","author":"I Ferrer","year":"2005","unstructured":"Ferrer I, Barrachina M, Puig B, Mart\u00ednez de Lagr\u00e1n M, Mart\u00ed E, Avila J et al (2005) Constitutive DYRK1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis 20:392\u2013400","journal-title":"Neurobiol Dis"},{"key":"2625_CR169","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","volume":"408","author":"J Bain","year":"2007","unstructured":"Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297\u2013315","journal-title":"Biochem J"},{"key":"2625_CR170","doi-asserted-by":"crossref","first-page":"e19264","DOI":"10.1371\/journal.pone.0019264","volume":"6","author":"D Frost","year":"2011","unstructured":"Frost D, Meechoovet B, Wang T, Gately S, Giorgetti M, Shcherbakova I et al (2011) \u03b2-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer\u2019s disease-related sites. PLoS One 6:e19264","journal-title":"PLoS One"},{"key":"2625_CR171","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0029-1186226","volume":"76","author":"A Ahmadu","year":"2010","unstructured":"Ahmadu A, Abdulkarim A, Grougnet R, Myrianthopoulos V, Tillequin F, Magiatis P et al (2010) Two new peltogynoids from Acacia nilotica delile with kinase inhibitory activity. Planta Med 76:458\u2013460","journal-title":"Planta Med"},{"key":"2625_CR172","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bj20021535","volume":"371","author":"J Bain","year":"2003","unstructured":"Bain J, McLauchlan H, Elliott M, Cohen P (2003) The specificities of protein kinase inhibitors: an update. Biochem J 371:199\u2013204","journal-title":"Biochem J"},{"key":"2625_CR173","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1021\/jm200274d","volume":"54","author":"M Debdab","year":"2011","unstructured":"Debdab M, Carreaux F, Renault S, Soundararajan M, Fedorov O, Filippakopoulos P et al (2011) Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem 54:4172\u20134186","journal-title":"J Med Chem"},{"key":"2625_CR174","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/jm301034u","volume":"55","author":"T Tahtouh","year":"2012","unstructured":"Tahtouh T, Elkins JM, Filippakopoulos P, Soundararajan M, Burgy G, Durieu E et al (2012) Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem 55:9312\u20139330","journal-title":"J Med Chem"},{"key":"2625_CR175","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1021\/jm200464w","volume":"54","author":"F Giraud","year":"2011","unstructured":"Giraud F, Alves G, Debiton E, Nauton L, Th\u00e9ry V, Durieu E et al (2011) Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives. J Med Chem 54:4474\u20134489","journal-title":"J Med Chem"},{"key":"2625_CR176","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.bmcl.2015.05.034","volume":"25","author":"RR Yadav","year":"2015","unstructured":"Yadav RR, Sharma S, Joshi P, Wani A, Vishwakarma RA, Kumar Bharate SB (2015) Meridianin derivatives as potent DYRK1A inhibitors and neuroprotective agents. Bioorg Med Chem Lett 25:2948\u20132952","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR177","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1021\/np400856h","volume":"77","author":"MA Beniddir","year":"2014","unstructured":"Beniddir MA, Le Borgne E, Iorga BI, Loaec N, Lozach O, Meijer L et al (2014) Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors. J Nat Prod 77:1117\u20131122","journal-title":"J Nat Prod"},{"key":"2625_CR178","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1016\/j.bmcl.2009.09.121","volume":"19","author":"BT Mott","year":"2009","unstructured":"Mott BT, Tanega C, Shen M, Maloney DJ, Shinn P, Leister W et al (2009) Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorg Med Chem Lett 19:6700\u20136705","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR179","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1016\/j.bmcl.2011.02.114","volume":"21","author":"AS Rosenthal","year":"2011","unstructured":"Rosenthal AS, Tanega C, Shen M, Mott BT, Bougie JM, Nguyen DT et al (2011) Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg Med Chem Lett 21:3152\u20133158","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms1090","volume":"86","author":"Y Ogawa","year":"2010","unstructured":"Ogawa Y, Nonaka Y, Goto T, Ohnishi E, Hiramatsu T, Kii I et al (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase DYRK1A. Nat Commun 86:1\u20139","journal-title":"Nat Commun"},{"key":"2625_CR181","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/jm700940h","volume":"51","author":"A Echalier","year":"2008","unstructured":"Echalier A, Bettayeb K, Ferandin Y, Lozach O, Cl\u00e9ment M, Valette A et al (2008) Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2\/cyclin A\/meriolin complex. J Med Chem 51:737\u2013751","journal-title":"J Med Chem"},{"key":"2625_CR182","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejmech.2012.01.040","volume":"49","author":"C Neagoie","year":"2012","unstructured":"Neagoie C, Vedrenne E, Buron F, M\u00e9rour JY, Rosca S, Bourg S et al (2012) Synthesis of chromeno [3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class. Eur J Med Chem 49:379\u2013396","journal-title":"Eur J Med Chem"},{"key":"2625_CR183","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1016\/j.bmcl.2014.09.017","volume":"24","author":"A Bruel","year":"2014","unstructured":"Bruel A, B\u00e9n\u00e9teau R, Chabanne M, Lozach O, Le Guevel R, Ravache M et al (2014) Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors. Bioorg Med Chem Lett 24:5037\u20135040","journal-title":"Bioorg Med Chem Lett"},{"key":"2625_CR184","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1432-1033.1993.tb18025.x","volume":"215","author":"H Sies","year":"1993","unstructured":"Sies H (1993) Strategies of antioxidant defense. Eur J Biochem 215:213\u2013219","journal-title":"Eur J Biochem"},{"key":"2625_CR185","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archneur.56.12.1449","volume":"56","author":"WR Markesbery","year":"1999","unstructured":"Markesbery WR (1999) The role of oxidative stress in Alzheimer disease. Arch Neurol 56:1449\u20131452","journal-title":"Arch Neurol"},{"key":"2625_CR186","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0006-2952(97)00062-2","volume":"54","author":"G Multhaup","year":"1997","unstructured":"Multhaup G, Ruppert T, Schlicksupp A, Hesse L, Beher D, Masters CL et al (1997) Reactive oxygen species and Alzheimer\u2019s disease. Biochem Pharmacol 54:533\u2013539","journal-title":"Biochem Pharmacol"},{"key":"2625_CR187","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-8993(97)81703-9","volume":"774","author":"JH Su","year":"1997","unstructured":"Su JH, Deng G, Cotman CW (1997) Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer\u2019s disease brain. Brain Res 774:193\u2013199","journal-title":"Brain Res"},{"key":"2625_CR188","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/35081571","volume":"2","author":"VW Young","year":"2001","unstructured":"Young VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502\u2013511","journal-title":"Nat Rev Neurosci"},{"key":"2625_CR189","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/01.jnen.0000228136.58062.bf","volume":"65","author":"A Nunomura","year":"2006","unstructured":"Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 65:631\u2013641","journal-title":"J Neuropathol Exp Neurol"},{"key":"2625_CR190","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archneur.61.1.82","volume":"61","author":"PP Zandi","year":"2004","unstructured":"Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT et al (2004) Cache county study group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the cache county study. Arch Neurol 61:82\u201388","journal-title":"Arch Neurol"},{"key":"2625_CR191","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1046\/j.1471-4159.2000.0742268.x","volume":"74","author":"S Bastianetto","year":"2000","unstructured":"Bastianetto S, Zheng WH, Quirion R (2000) The Ginkgo biloba extract (Egb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase. J Neurochem 74:2268\u20132277","journal-title":"J Neurochem"},{"key":"2625_CR192","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0891-5849(02)00883-3","volume":"33","author":"C Behl","year":"2002","unstructured":"Behl C, Moosmann B (2002) Antioxidant neuroprotection in Alzheimer\u2019s disease as preventive and therapeutic approach. Free Radic Biol Med 33:182\u2013191","journal-title":"Free Radic Biol Med"},{"key":"2625_CR193","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/mnfr.201000641","volume":"55","author":"SC Forester","year":"2011","unstructured":"Forester SC, Lambert JD (2011) Antioxidant effects of green tea. Mol Nutr Food Res 55:844\u2013854","journal-title":"Mol Nutr Food Res"},{"key":"2625_CR194","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/ijms11010107","volume":"11","author":"C Shi","year":"2010","unstructured":"Shi C, Liu J, Wu F, Yew DT (2010) Ginkgo biloba extract in Alzheimer\u2019s disease: from action mechanisms to medical practice. Int J Mol Sci 11:107\u2013123","journal-title":"Int J Mol Sci"},{"key":"2625_CR195","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1248\/bpb.32.1433","volume":"32","author":"HA Jung","year":"2009","unstructured":"Jung HA, Min BS, Yokozawa T, Lee JH, Kim YS, Choi JS (2009) Anti-Alzheimer and antioxidant activities of Coptidis rhizoma alkaloids. Biol Pharm Bull 32:1433\u20131438","journal-title":"Biol Pharm Bull"},{"key":"2625_CR196","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14:388\u2013405","journal-title":"Lancet Neurol"},{"key":"2625_CR197","first-page":"30185","volume":"S1552\u20135260","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P (2016) Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement S1552\u20135260:30185\u201330186","journal-title":"Alzheimers Dement"},{"key":"2625_CR198","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.biopha.2008.02.005","volume":"62","author":"RS Shah","year":"2008","unstructured":"Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ (2008) Current approaches in the treatment of Alzheimer\u2019s disease. Biomed Pharmacother 62:199\u2013207","journal-title":"Biomed Pharmacother"},{"key":"2625_CR199","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1073\/pnas.0503839103","volume":"103","author":"M Sastre","year":"2006","unstructured":"Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P et al (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPAR gamma. Proc Natl Acad Sci USA 103:443\u2013448","journal-title":"Proc Natl Acad Sci USA"},{"key":"2625_CR200","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.neurobiolaging.2010.06.014","volume":"33","author":"BL Wilkinson","year":"2012","unstructured":"Wilkinson BL, Cramer PE, Varvel NH, Reed-Geaghan E, Jiang Q, Szabo A et al (2012) Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer\u2019s disease. Neurobiol Aging 33:e21\u2013e32","journal-title":"Neurobiol Aging"},{"key":"2625_CR201","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archneur.65.12.noc80051","volume":"65","author":"BK Martin","year":"2008","unstructured":"ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S et al (2008) Cognitive function over time in the Alzheimer\u2019s Disease Anti-Inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896\u2013905","journal-title":"Arch Neurol"},{"key":"2625_CR202","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/13543776.2011.547479","volume":"21","author":"M Pettersson","year":"2011","unstructured":"Pettersson M, Kauffman GW, Am Ende CW, Patel NC, Stiff C, Tran TP et al (2011) Novel gamma-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Pat 21:205\u2013226","journal-title":"Expert Opin Ther Pat"},{"key":"2625_CR203","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/clc.22361","volume":"38","author":"BL Wanamaker","year":"2015","unstructured":"Wanamaker BL, Swiger KJ, Blumenthal RS, Martin SS (2015) Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol 38:243\u2013250","journal-title":"Clin Cardiol"},{"key":"2625_CR204","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","volume":"356","author":"H Jick","year":"2000","unstructured":"Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356:1627\u20131631","journal-title":"Lancet"},{"key":"2625_CR205","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","volume":"74","author":"HH Feldman","year":"2010","unstructured":"Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW et al (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74:956\u2013964","journal-title":"Neurology"},{"key":"2625_CR206","doi-asserted-by":"crossref","unstructured":"McGuinness B, O\u2019Hare J, Craig D, Bullock R, Malouf R, Passmore P (2010) Statins for the treatment of dementia. Cochrane Database Syst Rev 8:CD007514","DOI":"10.1002\/14651858.CD007514.pub2"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-016-2625-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-016-2625-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-016-2625-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T18:49:25Z","timestamp":1656614965000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-016-2625-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":206,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["2625"],"URL":"https:\/\/doi.org\/10.1007\/s10072-016-2625-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,1]]}}}